GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (DUB:OVXA) » Definitions » Return-on-Tangible-Equity

Ovoca Bio (DUB:OVXA) Return-on-Tangible-Equity : -104.98% (As of Jun. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Ovoca Bio Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ovoca Bio's annualized net income for the quarter that ended in Jun. 2024 was €-2.49 Mil. Ovoca Bio's average shareholder tangible equity for the quarter that ended in Jun. 2024 was €2.37 Mil. Therefore, Ovoca Bio's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 was -104.98%.

The historical rank and industry rank for Ovoca Bio's Return-on-Tangible-Equity or its related term are showing as below:

DUB:OVXA' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -164.69   Med: -14.38   Max: -1.66
Current: -154.08

During the past 13 years, Ovoca Bio's highest Return-on-Tangible-Equity was -1.66%. The lowest was -164.69%. And the median was -14.38%.

DUB:OVXA's Return-on-Tangible-Equity is ranked worse than
81.37% of 1256 companies
in the Biotechnology industry
Industry Median: -48.155 vs DUB:OVXA: -154.08

Ovoca Bio Return-on-Tangible-Equity Historical Data

The historical data trend for Ovoca Bio's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovoca Bio Return-on-Tangible-Equity Chart

Ovoca Bio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.41 -15.63 -52.32 -103.33 -164.69

Ovoca Bio Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -222.45 2.80 -174.94 -197.46 -104.98

Competitive Comparison of Ovoca Bio's Return-on-Tangible-Equity

For the Biotechnology subindustry, Ovoca Bio's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovoca Bio's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovoca Bio's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Ovoca Bio's Return-on-Tangible-Equity falls into.



Ovoca Bio Return-on-Tangible-Equity Calculation

Ovoca Bio's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-4.702/( (3.209+2.501 )/ 2 )
=-4.702/2.855
=-164.69 %

Ovoca Bio's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=-2.488/( (2.501+2.239)/ 2 )
=-2.488/2.37
=-104.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Ovoca Bio  (DUB:OVXA) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Ovoca Bio Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Ovoca Bio's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovoca Bio Business Description

Traded in Other Exchanges
Address
17 Pembroke Street Upper, Dublin, IRL, D02 AT22
Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.

Ovoca Bio Headlines

No Headlines